First impressions may be key to your patient’s acceptance of Optune. The table inside this folder includes patient-friendly language to help you and your staff answer those important initial questions from patients and caregivers and educate them about Optune. The enclosed tear pad provides patients with a take-home summary of the key information from these first conversations. The topics and responses are based on interactions between Novocure® and patients and healthcare providers on the phone, online, and in market research.
Discuss the overall treatment plan with the multidisciplinary team soon after diagnosis

In discussions with HCPs, Novocure® has identified a 4-step process to seamlessly integrate Optune® into their clinical practice. This folder describes the language a multidisciplinary team of HCPs can use in Step 1, discussing the treatment plan with the patient and caregiver.

It is important to align the entire multidisciplinary team to communicate consistently to the patient and caregivers. Patients may find it difficult to retain large amounts of information at this overwhelming time, so consistent information during several conversations is key.

Patient resources

**Buddy Program**
The Optune Buddy Program connects patients with Optune users and their caregivers.

**Optune.com**
An online portal to all the resources of Optune

GBM, glioblastoma; HCP, healthcare professional; RT, radiation therapy; TMZ, temozolomide.
Indications For Use

Optune® is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications
Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions
Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please visit Optune.com/IFU for Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.
Topics important to patients’ first impressions of Optune®

<table>
<thead>
<tr>
<th>Question</th>
<th>Patient-language answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>“What is Optune?”</td>
<td>“Optune is a wearable, portable, FDA-approved treatment for GBM. When it is turned on, it creates low-intensity, wavelike electric fields called Tumor Treating Fields, or TTFields. These TTFields are delivered by transducer arrays to the GBM tumor.” “More than 10,000 patients have been treated with Optune.” 1,2</td>
</tr>
<tr>
<td>“How does Optune work?”</td>
<td>“Optune works differently from surgery, radiation, or chemotherapy. TTFields created by Optune can slow or stop GBM tumor cells from dividing and may cause some cells to die.” 2</td>
</tr>
<tr>
<td>“Can Optune help me live longer?”</td>
<td>“In people with newly diagnosed GBM, Optune has been proven to extend survival.” 2 “In a large clinical study, people who added Optune to chemotherapy had a greater opportunity to live longer than those who had chemotherapy alone. Nearly half of people (43%) on Optune plus chemo had better survival at 2 years, compared with 31% on chemo alone. At 5 years, patients using Optune + chemo had better survival (13%) than patients on chemo alone (5%).” 2</td>
</tr>
<tr>
<td>“How will Optune affect my daily life?”</td>
<td>“The people in the study maintained their mental, emotional, and physical well-being longer than those on chemotherapy alone.” 3,4</td>
</tr>
<tr>
<td>“What are the side effects?”</td>
<td>“Optune treats where your GBM is located without increasing chemotherapy-related side effects. TTFields do not enter the bloodstream like a drug, so Optune did not significantly increase chemotherapy-related side effects compared to TMZ alone.” 2</td>
</tr>
<tr>
<td>“How would Optune fit into my treatment plan?”</td>
<td>“In newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) after surgery and radiation with chemotherapy.”</td>
</tr>
<tr>
<td>“How can I get more help and information?”</td>
<td>“The Novocure® nCompass™ program provides complete patient support every step of the way. Visit <a href="https://www.optune.com">Optune.com</a> to learn more about the complete services available to you.”</td>
</tr>
</tbody>
</table>

Visit [www.optune.com/hcp/resources](https://www.optune.com/hcp/resources) to learn more.

*Patients with GBM treated commercially and clinically with Optune + TMZ in the EF-14 trial.1
1Measured up to 1 year.

Please visit [Optune.com/IFU](https://www.optune.com/IFU) for Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.
Important Safety Information

Indications For Use

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma multiforme (GBM).

Warnings and Precautions

- Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
- The most common (>10%) adverse reactions that have been reported with Optune treatment are dry skin and skin irritation. These reactions are typically transient and occur during treatment, rarely leading to treatment discontinuation. Rarely, Observed events during treatment were severe allergic reactions such as shock and respiratory failure.
- In a phase 3 randomized clinical trial, 1,078 patients with newly diagnosed GBM received maintenance treatment with Optune plus temozolomide or temozolomide alone. At 1 year, 50.3% of patients treated with Optune plus temozolomide were free from progression compared with 38.3% of patients treated with temozolomide alone (Hazard Ratio: 0.66, 95% CI: 0.54—0.81, p < 0.001). The median overall survival was 16.5 months for patients treated with Optune plus temozolomide and 12.3 months for patients treated with temozolomide alone (HR: 0.71, 95% CI: 0.58—0.87, p < 0.001). Adverse reactions of any grade reported during the maintenance phase of the trial are listed in the table below.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Toxicity</th>
<th>Optune plus Temozolomide</th>
<th>Temozolomide alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Thrombocytopenia</td>
<td>10% (21/213)</td>
<td>1.8% (12/670)</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>24% (52/213)</td>
<td>14.5% (98/670)</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>17% (35/213)</td>
<td>11.5% (78/670)</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>13% (28/213)</td>
<td>9.1% (61/670)</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>33% (70/213)</td>
<td>14.5% (98/670)</td>
</tr>
<tr>
<td></td>
<td>Medical device site reaction</td>
<td>40% (85/213)</td>
<td>3.7% (25/670)</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>26% (55/213)</td>
<td>15.6% (106/670)</td>
</tr>
<tr>
<td></td>
<td>Convulsions</td>
<td>4% (9/213)</td>
<td>1.2% (8/670)</td>
</tr>
</tbody>
</table>

The safety and effectiveness of Optune in patients with newly diagnosed GBM with a history of radiation necrosis, radiation induced changes, brain metastases, or with severe gliomata is not established. The use of Optune in patients with newly diagnosed GBM with any of these characteristics should be discussed with patients and caregivers, as the safety and effectiveness of Optune in these populations have not been established.

Contraindications

- Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
- Although Optune treatment may be continued during the use of temozolomide, ongoing use of temozolomide may temporarily interfere with Optune treatment.


Images labeled as Optune users depict actual patients.

Patient images reflect the health status of the patients at the time each photo was taken.
An Introduction to Optune®

Optune may be new to you. Here are a few answers that helped other patients with GBM and their caregivers decide if Optune was right for them.

What is Optune?
Optune is a wearable, portable, FDA-approved treatment for glioblastoma.

How will Optune affect my daily life?
The people who used Optune in a large clinical study maintained their mental, emotional, and physical well-being longer than those on chemotherapy alone. 2,*

You can get continuous treatment with Optune almost anywhere. If your doctor says it’s okay, you can use Optune while you go about your daily routine at work, while traveling, and at social functions.

What are the side effects?
• Optune does not significantly increase chemo-like side effects

Can Optune help me live longer?
In a large clinical study, people who added Optune to chemotherapy had a greater opportunity to live longer than those who had chemotherapy alone. Nearly half of people (43%) on Optune plus chemo were alive at 2 years, compared with 31% on chemo alone. At 5 years, more of the patients using Optune were still alive: 13%, compared to 5% for those using chemo alone. 1

How would Optune fit into my treatment plan?
In newly diagnosed GBM, Optune is used together with temozolomide—known as Temodar® or TMZ—after surgery and radiation with chemotherapy.

In recurrent GBM, Optune is used alone after treatments like surgery and radiation.

Visit Optune.com for more resources and to hear from Optune users.

Notes:

*Measured up to 1 year.

Please visit Optune.com/Safety for Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.
Important Safety Information

Newly diagnosed GBM
In newly diagnosed GBM, Optune® is used together with a chemotherapy called temozolomide (TMZ) if:
• Your cancer is confirmed by your healthcare professional AND
• You have had surgery to remove as much of the tumor as possible

Recurrent GBM
If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:
• You have tried surgery and radiation and they did not work or are no longer working AND
• You have tried chemotherapy and your GBM has been confirmed by your healthcare professional

Who should not use Optune?
Optune is not for everyone. Talk to your doctor if you have:
• An implanted medical device (programmable shunt), skull defect (missing bone with no replacement), or bullet fragment. Optune has not been tested in people with implanted electronic devices, which may cause the devices not to work properly, and Optune has not been tested in people with skull defects or bullet fragments, which may cause Optune not to work properly
• A known sensitivity to conductive hydrogels (the gel on the arrays placed on the scalp like the ones used on EKGs). When Optune comes into contact with the skin, it may cause more redness and itching or may rarely cause a life-threatening allergic reaction

Do not use Optune if you are pregnant or planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.

What should I know before using Optune?
Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune.
• Do not use any parts that did not come with the Optune Treatment Kit sent to you by Novocure or given to you by your doctor
• Do not get the device or transducer arrays wet
• If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune treatment

What are the possible side effects of Optune?
Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.
The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

Talk to your doctor if you have any of these side effects or questions.

Please visit Optune.com/Safety for Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Images labeled as Optune users depict actual patients. Patient images reflect the health status of the patients at the time each photo was taken.